Utah Med Prods Stock Price, News & Analysis

Utah Medical Products (NASDAQ:UTMD) reported 3Q and 9M 2025 results impacted by global trade disruptions and FX movements. Total WW sales fell 1.9% (3Q) and 7.2% (9M) vs prior-year periods; constant-currency sales were modestly helped by FX (+$114 in 3Q, +$244 in 9M). Gross profit margin narrowed (3Q: 57.1% vs 58.0% prior) and operating income margin declined (3Q: 26.6% vs 33.4% prior) partly due to a $395 bad-debt reserve tied to an OUS distributor cancellation and higher operating expenses. Litigation and UK amortization continue to affect G&A. Balance sheet strengthened with higher current ratio, lower liabilities, higher equity, $3,006 paid in dividends and $7,361 used for share repurchases through 9M 2025.

Utah Medical Products (NASDAQ:UTMD) has announced a quarterly cash dividend of $0.305 per share of common stock. The dividend will be payable on October 2, 2025, to stockholders of record at the close of business on September 17, 2025.

This represents a 1.7% increase compared to the dividend declared in the same quarter of the previous year. The company specializes in healthcare products for women and their babies, manufacturing specialty medical devices used by clinicians globally.

Utah Medical Products (NASDAQ:UTMD) reported Q2 2025 financial results with consolidated revenues of $9.95 million, down 4.3% from Q2 2024. First half 2025 revenues decreased 9.6% to $19.66 million. The decline was primarily attributed to reduced sales to PendoTECH, representing 71% of Q2 decline and 86% of 1H decline.

Key metrics include Q2 2025 gross profit margin of 56.2% (vs 60.1% in Q2 2024), operating income margin of 32.1% (vs 33.1%), and net income margin of 30.6% (vs 33.2%). The company maintained a strong balance sheet with $82.2 million in cash and investments as of June 30, 2025, with no debt.

During 1H 2025, UTMD paid $2.0 million in dividends and repurchased $6.7 million of common stock while investing $0.2 million in capital expenditures.

Utah Medical Products (NASDAQ: UTMD) has announced a quarterly cash dividend of $0.305 per share of common stock. The dividend will be payable on July 3, 2025, to stockholders of record at the close of business on June 16, 2025. This represents a 1.7% increase compared to the dividend declared in the same quarter of the previous year. UTMD specializes in healthcare products for women and their babies, manufacturing and marketing specialty medical devices that are recognized globally across over 100 countries.

Utah Medical Products reported its Q1 2025 financial results, showing declines across key metrics compared to Q1 2024. The company experienced a 14.4% decrease in revenues, with sales dropping primarily due to reduced OEM sales to PendoTECH, which accounted for 91% of the decline.

Key financial metrics show:

• Gross Profit declined 18.1%
• Operating Income decreased 18.8%
• Net Income fell 23.1%
• Earnings Per Share reduced by 16.0%

Despite using $4.4 million in cash for share repurchases, dividends, and equipment purchases, the company maintained a strong balance sheet with $83.3 million in cash. Domestic sales excluding PendoTECH were 9% higher, while international sales were 14% lower in USD terms. The company's EBITDA for Q1 2025 was $4.65 million, supporting their year 2025 target of $18 million.

Utah Medical Products (Nasdaq:UTMD) has announced a quarterly cash dividend of $0.305 per share of common stock. The dividend will be payable on April 3, 2025, to stockholders of record at the close of business on March 14, 2025. This represents a 1.7% increase compared to the dividend declared in the same quarter of the previous year.

The company specializes in healthcare products for women and their babies, developing and manufacturing specialty medical devices that are recognized as standard equipment by clinicians in over 100 countries worldwide.

Utah Medical Products (NASDAQ:UTMD) reported significant declines in its 2024 financial performance, with revenues down 19%, net income down 17%, and EPS down 13% compared to 2023. The company's stock price declined 27%, which enabled UTMD to repurchase over 8% of its shares.

The $9.3 million decline in annual revenues was primarily attributed to three factors: a 69% decline ($5.9M) in PendoTECH OEM sales, a 20% reduction ($2.1M) in OUS distributor sales (excluding Filshie), and a 12% decrease ($1.5M) in worldwide Filshie device sales.

Despite lower sales, profit margins remained relatively stable. The company maintained its gross profit margin at 59.0% in 2024 (vs 59.8% in 2023) through manufacturing personnel reductions and closing the second production shift in Utah. The balance sheet remained strong with $83.0 million in cash and investments as of December 31, 2024, though down from $92.9 million in 2023.

Utah Medical Products (UTMD) announced two key developments: First, the appointment of Carrie Leigh to its Board of Directors. Leigh, who worked in direct sales positions for UTMD from 2004 to 2016, brings valuable experience from her role as manager of Global Direct End User Sales. Second, the company increased its quarterly cash dividend by 1.7% to $0.305 per share, payable on January 3, 2025, to shareholders of record as of December 16, 2024.

Utah Medical Products (NASDAQ:UTMD) reported weaker Q3 and 9M 2024 revenues but improved bottom-line performance compared to projections. Q3 worldwide sales declined 20% to $10,005, with domestic sales down 21.7% and international sales down 17.6%. The decline was primarily driven by lower sales to PendoTECH ($1,704 lower in Q3) and reduced Filshie Clip System sales. Despite revenue challenges, profit margins remained relatively stable, with Q3 2024 gross profit margin at 58.0% versus 58.8% in Q3 2023. The company's balance sheet remained strong despite paying $3,222 in dividends and using $13,259 for share repurchases. Management now expects total 2024 consolidated sales to decline 18-19% compared to 2023.